WASHINGTON Dec 14 U.S. antitrust authorities
have cleared GlaxoSmithKline Plc (GSK.L) to buy privately held
heart drug specialist Reliant Pharmaceuticals.
The Federal Trade Commission announced that antitrust
authorities had found no reason to oppose the deal in a listing
of completed merger reviews that it issues periodically.
Glaxo, Europe's biggest drugmaker, said last month it
planned to buy Reliant for $1.65 billion in cash.
Reliant, which recorded net sales of $341 million in the
nine months ending Sept. 30, has a portfolio of specialty drugs
for heart disease, including U.S. rights to Lovaza, an omega-3
treatment for patients with very high levels of triglycerides.
(Reporting by Diane Bartz; Editing by Brian Moss)